Canada authorises remdesivir to treat patients of severe Covid-19

Canada has announced its authorisation for using the drug remdesivir for treating patients suffering severe symptoms of Covid-19 who have pneumonia and require extra oxygen to help them breathe.

 

 

Remdesivir is the first drug that Canada has authorised for the treatment of Covid-19, according to a press release on Tuesday from Health Canada, Xinhua reported.

 

The drug, manufactured by Gilead Sciences Canada, Inc., is authorised for use in adults and adolescents with a bodyweight of at least 40 kg. The authorization includes a full six-week scientific review.

 

Gilead Sciences Canada, Inc. did not seek authorisation for an indication for use of remdesivir to treat children or pregnant women, Health Canada said.

 

Remdesivir is administered intravenously and will be used only in healthcare facilities where patients can be closely monitored.

 

As part of the conditional authorization, Gilead Sciences Canada, Inc. will submit to Health Canada drug safety monitoring reports, including reports on all serious adverse drug reactions.

 

Health Canada will continue to closely monitor the safety of remdesivir in Canada and will take prompt action should any safety concerns arise, according to the press release.

--IANS

pgh/


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel